View More View Less
  • 1 Debreceni Egyetem, Általános Orvostudományi Kar, Orvos- és Egészségtudományi Centrum II. Belgyógyászati Klinika, Hematológiai Tanszék, Belgyógyászati Intézet Debrecen Nagyerdei krt. 98. 4032
Restricted access

Purchase article

USD  $25.00

1 year subscription (Individual Only)

USD  $1,070.00

A köpenysejtes lymphoma egyesíti az indolens és az agresszív lymphomák rossz tulajdonságait, azaz az agresszív lymphomákhoz hasonlóan gyors lefolyású és progresszív, és az indolens lymphomákhoz hasonlóan kemoterápiával, illetve immunokemoterápiával nem gyógyítható. Az elmúlt években számos olyan előrelépés történt, amely nagyban javítja a köpenysejtes lymphomás betegek életkilátásait. Az intenzifikált immunokemoterápiára jól válaszoló betegek első komplett remissziójában konszolidációs kezelést kell végezni. A konszolidáció: rituximab és citozin-arabinosidal intenzifikált kezelést követően a lehetőleg sugárterápiát is alkalmazó kondicionáló kezelés és autológ transzplantáció, amely a várható átlagos túlélést minden korábbi adathoz képest lényegesen meghosszabbítja (átlag 2,5–3 év helyett valószínűleg 7–10 év között). A visszaeső betegek kezelésére pedig számos új lehetőség kínálkozik, amelyek közül az egyik legfontosabbat az Egyesült Államokban már erre a betegségre is törzskönyvezték. Az új terápiás lehetőségek áttekintésével foglalkozik a közlemény.

  • Lennert, K., Feller, A. C.: Histopathology of non-Hodgkin lymphomas based upon the updated Kiel classification. Springer Verlag, Berlin, 1992, 312–321.

    Feller A. C. , '', in Histopathology of non-Hodgkin lymphomas based upon the updated Kiel classification , (1992 ) -.

  • Swerdlow, S. H., Campo, E., Seto, M. és mtsa: Mantle cell lymphoma. In: WHO classification of tumours of haematopoietic and lymphoid tissues, ARC, Lyon, 2008.

    Seto M. , '', in WHO classification of tumours of haematopoietic and lymphoid tissues , (2008 ) -.

  • Rosta A., Matolcsy A.: Köpenysejtes lymphoma. In: Hematológiai betegségek atlasza. Szerk.: Matolcsy A., Udvardy M., Kopper L. Medicina Könyvkiadó, Budapest, 2006, 268–273.

    Matolcsy A. , '', in Hematológiai betegségek atlasza , (2006 ) -.

  • Smith, M. R.: Mantle cell lymphoma: advances in biology and therapy. Curr. Opin. Hematol., 2008, 15 , 415–421.

    Smith M. R. , 'Mantle cell lymphoma: advances in biology and therapy ' (2008 ) 15 Curr. Opin. Hematol. : 415 -421.

    • Search Google Scholar
  • Hiddemann, M. Dreyling, M., Tiemann, C. és mtsai for Unterhalt for the European Mantle Cell Study Group: Mantle cell lymphomas. Haematologica, 1999, 84 , 93–95.

    Hiddemann M. Dreyling, M., Tiemann, C. , 'Mantle cell lymphomas ' (1999 ) 84 Haematologica : 93 -95.

    • Search Google Scholar
  • Dreyling, M., Bergsagel, P. L., Gordon, L. I. és mtsa: Mantle cell lymphoma and other t(11;14) disorders: How biology can drive therapy. ASCO Educational book 2006, 476–484.

  • Dreyling, M., Unterhalt, M., Weigert, O. és mtsa: Therapy of mantle cell lymphoma. Internist (Berl.), 2007, 48 , 382–388.

    Weigert O. , 'Therapy of mantle cell lymphoma ' (2007 ) 48 Internist (Berl.) : 382 -388.

  • Schulz, H., Bohlius, J. F., Trelle, S. és mtsai: Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J. Natl. Cancer. Inst., 2007, 99 , 706–714.

    Trelle S. , 'Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis ' (2007 ) 99 J. Natl. Cancer. Inst. : 706 -714.

    • Search Google Scholar
  • Weigert, O., Unterhalt, M., Hiddemann, W. és mtsa: Current management of mantle cell lymphoma. Drugs, 2007, 67 , 1689–1702.

    Hiddemann W. , 'Current management of mantle cell lymphoma ' (2007 ) 67 Drugs : 1689 -1702.

  • Forstpointner, R., Unterhalt, M., Dreyling, M. és mtsai: Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide and mitoxantrone (R-FCM) in patients with relapsed and refractory follicular and mantle cell lymphomas – Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood, 2006, 108 , 4003–4008.

    Dreyling M. , 'Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide and mitoxantrone (R-FCM) in patients with relapsed and refractory follicular and mantle cell lymphomas – Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG) ' (2006 ) 108 Blood : 4003 -4008.

    • Search Google Scholar
  • Hiddemann, M., Dreyling, M., Unterhalt, M.: Rituximab plus chemotherapy in follicular and mantle cell lymphomas. Semin. Oncol., 2003, 81 , 16–20.

    Unterhalt M. , 'Rituximab plus chemotherapy in follicular and mantle cell lymphomas ' (2003 ) 81 Semin. Oncol. : 16 -20.

    • Search Google Scholar
  • Cheson, B. D., Pfistner, B., Juweid, M. E.: Revised response criteria for malignant lymphoma. J. Clin. Oncol., 2007, 25 , 579–586.

    Juweid M. E. , 'Revised response criteria for malignant lymphoma ' (2007 ) 25 J. Clin. Oncol. : 579 -586.

    • Search Google Scholar
  • Forstpointner, R., Dreyling, M., Repp, R.: The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared to FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas – results of a prospective randomized study of the German Low Grade Lymphoma Study Group. Blood, 2004, 104 , 3064–3071.

    Repp R. , 'The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared to FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas – results of a prospective randomized study of the German Low Grade Lymphoma Study Group ' (2004 ) 104 Blood : 3064 -3071.

    • Search Google Scholar
  • Lenz, G., Dreyling, M., Unterhalt, M. és mtsa: Current strategies in the treatment of advanced stage mantle cell lymphoma. Dtsch. Med. Wochenschr., 2004, 129 , 2429–2433.

    Unterhalt M. , 'Current strategies in the treatment of advanced stage mantle cell lymphoma ' (2004 ) 129 Dtsch. Med. Wochenschr. : 2429 -2433.

    • Search Google Scholar
  • Hiddemann, W., Dreyling, M.: Mantle cell lymphoma: Therapeutic strategies are different from CLL. Curr. Treat. Options Oncol., 2003, 4 , 219–226.

    Dreyling M. , 'Mantle cell lymphoma: Therapeutic strategies are different from CLL ' (2003 ) 4 Curr. Treat. Options Oncol. : 219 -226.

    • Search Google Scholar
  • Lenz, G., Dreyling, M., Hoster, E. és mtsai: Immuno-chemotherapy with rituximab and CHOP significantly improves response and time to treatment failure but not long-term outcome in patients with previously untreated mantle cell lymphoma – Results of a prospective randomized Trial of the German Low Grade Lymphoma Study Group (GLSG). J. Clin. Oncol., 2005, 23 , 1984–1992.

    Hoster E. , 'Immuno-chemotherapy with rituximab and CHOP significantly improves response and time to treatment failure but not long-term outcome in patients with previously untreated mantle cell lymphoma – Results of a prospective randomized Trial of the German Low Grade Lymphoma Study Group (GLSG) ' (2005 ) 23 J. Clin. Oncol. : 1984 -1992.

    • Search Google Scholar
  • Dreyling, M., Lenz, G., Hoster, E. és mtsai: Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle cell lymphoma – Results of a Prospective Randomized Trial of the European MCL Network. Blood, 2005, 105 , 2677–2684.

    Hoster E. , 'Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle cell lymphoma – Results of a Prospective Randomized Trial of the European MCL Network ' (2005 ) 105 Blood : 2677 -2684.

    • Search Google Scholar
  • Lenz, G., Dreyling, M., Hiddemann, W.: Mantle cell lymphoma: established therapeutic options and future directions. Ann. Hematol., 2004, 83 , 71–77.

    Hiddemann W. , 'Mantle cell lymphoma: established therapeutic options and future directions ' (2004 ) 83 Ann. Hematol. : 71 -77.

    • Search Google Scholar
  • Lenz, G., Dreyling, M.: Does the combination of rituximab and thalidomide influence the long-term perspectives of advanced-stage MCL? Nat. Clin. Pract. Oncol., 2005, 2 , 72–73.

    Dreyling M. , 'Does the combination of rituximab and thalidomide influence the long-term perspectives of advanced-stage MCL? ' (2005 ) 2 Nat. Clin. Pract. Oncol. : 72 -73.

    • Search Google Scholar

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
Sep 2020 16 0 0
Oct 2020 5 0 1
Nov 2020 6 0 0
Dec 2020 8 0 2
Jan 2021 1 0 0
Feb 2021 1 0 0
Mar 2021 7 0 0